1. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy
- Author
-
Gandhi, Rajesh T., O’Neill, David, Bosch, Ronald J., Chan, Ellen S., Bucy, R. Pat, Shopis, Janet, Baglyos, Lynn, Adams, Elizabeth, Fox, Lawrence, Purdue, Lynette, Marshak, Ann, Flynn, Theresa, Masih, Reena, Schock, Barbara, Mildvan, Donna, Schlesinger, Sarah J., Marovich, Mary A., Bhardwaj, Nina, and Jacobson, Jeffrey M.
- Subjects
- *
ANTIRETROVIRAL agents , *HIV-positive persons , *DENDRITIC cells , *CLINICAL trials , *AIDS vaccines , *IMMUNE response , *TARGETED drug delivery , *HEMOCYANIN , *DRUG efficacy - Abstract
Abstract: Targeting canarypox (CP)-HIV vaccine to dendritic cells (DCs) elicits anti-HIV-1 immune responses in vitro. We conducted a phase I/II clinical trial to evaluate whether adding DC to a CP-HIV vaccine improved virologic control during analytic treatment interruption (ATI) in HIV-1-infected subjects. Twenty-nine subjects on suppressive antiretroviral therapy were randomized to vaccination with autologous DCs infected with CP-HIV+keyhole limpet hemocyanin (KLH) (arm A, n =14) or CP-HIV+KLH alone (arm B, n =15). The mean viral load (VL) setpoint during ATI did not differ between subjects in arms A and B. A higher percentage of subjects in the DC group had a VL setpoint <5000c/mL during ATI (4/13 or 31% in arm A compared with 0/13 in arm B, p =0.096), but virologic control was transient. Subjects in arm A had a greater increase in KLH lymphoproliferative response than subjects in arm B; however, summed ELISPOT responses to HIV-1 antigens did not differ by treatment arm. We conclude that a DC-CP-HIV vaccine is well-tolerated in HIV-1-infected patients, but does not lower VL setpoint during ATI compared with CP-HIV alone. New methods to enhance the immunogenicity and antiviral efficacy of DC-based vaccines for HIV-1 infection are needed. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF